Kopran Ltd vs Lincoln Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Kopran Ltd is ₹ 164.25 as of 06 May 15:30 . The P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 yearsThe P/E Ratio of Lincoln Pharmaceuticals Ltd changed from 7.2 on March 2021 to 13.4 on March 2025 . This represents a CAGR of 13.23% over 5 years The Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 yearsThe Market Cap of Lincoln Pharmaceuticals Ltd changed from ₹ 449.4 crore on March 2021 to ₹ 1104 crore on March 2025 . This represents a CAGR of 19.71% over 5 years The revenue of Kopran Ltd for the Dec '25 is ₹ 194.35 crore as compare to the Sep '25 revenue of ₹ 117.93 crore. This represent the growth of 64.8% The revenue of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 181.47 crore as compare to the Sep '25 revenue of ₹ 170.6 crore. This represent the growth of 6.37% The ebitda of Kopran Ltd for the Dec '25 is ₹ 17.83 crore as compare to the Sep '25 ebitda of ₹ -5.25 crore. This represent the decline of -439% The ebitda of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 38.74 crore as compare to the Sep '25 ebitda of ₹ 32.66 crore. This represent the growth of 18.62% The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 9.34 crore over 7 quarters. This represents a CAGR of -9.39% The net profit of Lincoln Pharmaceuticals Ltd changed from ₹ 23.67 crore to ₹ 28.6 crore over 7 quarters. This represents a CAGR of 11.42% The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 yearsThe Dividend Payout of Lincoln Pharmaceuticals Ltd changed from 4.83 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of -1.94% over 5 years .

About Kopran Ltd

Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95.
All the assets and business of the erstwhile partnership were transferred to the Company.
The Company is engaged in the business of manufacturing and trading of pharmaceutical products.
The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982.
It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments.

FAQs for the comparison of Kopran Ltd and Lincoln Pharmaceuticals Ltd

Which company has a larger market capitalization, Kopran Ltd or Lincoln Pharmaceuticals Ltd?

Market cap of Kopran Ltd is 793 Cr while Market cap of Lincoln Pharmaceuticals Ltd is 1,346 Cr

What are the key factors driving the stock performance of Kopran Ltd and Lincoln Pharmaceuticals Ltd?

The stock performance of Kopran Ltd and Lincoln Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kopran Ltd and Lincoln Pharmaceuticals Ltd?

As of May 6, 2026, the Kopran Ltd stock price is INR ₹164.25. On the other hand, Lincoln Pharmaceuticals Ltd stock price is INR ₹672.25.

How do dividend payouts of Kopran Ltd and Lincoln Pharmaceuticals Ltd compare?

To compare the dividend payouts of Kopran Ltd and Lincoln Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.